RGNX
Income statement / Annual
Last year (2023), REGENXBIO Inc.'s total revenue was $90.24 M,
a decrease of 19.94% from the previous year.
In 2023, REGENXBIO Inc.'s net income was -$263.49 M.
See REGENXBIO Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$90.24 M
|
$112.72 M
|
$470.35 M
|
$154.57 M
|
$35.23 M
|
$218.51 M
|
$10.39 M
|
$4.59 M
|
$7.59 M
|
$6.12 M
|
| Cost of Revenue |
$54.53 M |
$54.55 M |
$51.83 M |
$35.71 M |
$8.24 M |
$9.64 M |
$1.71 M |
$959,000.00 |
$1.50 M |
$1.01 M |
| Gross Profit |
$35.71 M |
$58.18 M |
$418.51 M |
$118.85 M |
$26.99 M |
$208.87 M |
$8.68 M |
$3.63 M |
$6.09 M |
$5.11 M |
| Gross Profit Ratio |
0.4 |
0.52 |
0.89 |
0.77 |
0.77 |
0.96 |
0.84 |
0.79 |
0.8 |
0.84 |
| Research and Development
Expenses |
$214.95 M
|
$242.45 M
|
$181.44 M
|
$166.29 M
|
$124.19 M
|
$83.87 M
|
$57.22 M
|
$45.48 M
|
$17.28 M
|
$4.96 M
|
| General & Administrative
Expenses |
$88.49 M
|
$85.28 M
|
$79.33 M
|
$63.82 M
|
$51.82 M
|
$36.85 M
|
$27.23 M
|
$23.59 M
|
$11.91 M
|
$3.85 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$88.49 M
|
$85.28 M
|
$79.33 M
|
$63.82 M
|
$51.82 M
|
$36.85 M
|
$27.23 M
|
$23.59 M
|
$11.91 M
|
$3.85 M
|
| Other Expenses |
-$397,000.00 |
-$6.68 M |
-$2.24 M |
$7.98 M |
-$10,000.00 |
$42,000.00 |
$116,000.00 |
-$102,000.00 |
-$26,000.00 |
-$47,000.00 |
| Operating Expenses |
$303.84 M |
$321.06 M |
$258.53 M |
$238.09 M |
$175.99 M |
$120.77 M |
$84.57 M |
$68.97 M |
$29.17 M |
$8.77 M |
| Cost And Expenses |
$358.37 M |
$375.60 M |
$310.37 M |
$273.80 M |
$184.23 M |
$130.41 M |
$86.28 M |
$69.93 M |
$30.67 M |
$9.77 M |
| Interest Income |
$9.14 M |
$342,000.00 |
$719,000.00 |
$4.27 M |
$2.95 M |
$8.95 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$6.86 M |
$23.25 M |
$26.28 M |
$771,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$20,000.00 |
$321,000.00 |
| Depreciation &
Amortization |
$17.32 M
|
$12.91 M
|
$9.56 M
|
$8.41 M
|
$7.15 M
|
$3.98 M
|
$2.69 M
|
$544,000.00
|
$80,000.00
|
$30,000.00
|
| EBITDA |
-$250.81 M
|
-$262.53 M
|
$160.70 M
|
-$114.96 M
|
-$197.56 M
|
$81.03 M
|
-$78.60 M
|
-$65.34 M
|
-$23.08 M
|
-$3.65 M
|
| EBITDA Ratio |
-2.78 |
-2.33 |
0.34 |
-0.74 |
-5.61 |
0.37 |
-7.56 |
-14.24 |
-3.04 |
-0.6 |
| Operating Income Ratio
|
-2.97
|
-2.33
|
0.34
|
-0.77
|
-4.23
|
0.4
|
-7.3
|
-14.24
|
-3.05
|
-0.6
|
| Total Other
Income/Expenses Net |
$4.48 M
|
-$17.53 M
|
-$18.73 M
|
$13.22 M
|
$51.51 M
|
$7.07 M
|
$2.72 M
|
$1.94 M
|
$289,000.00
|
-$30,000.00
|
| Income Before Tax |
-$263.65 M |
-$280.41 M |
$141.25 M |
-$106.01 M |
-$97.49 M |
$104.12 M |
-$73.17 M |
-$63.40 M |
-$22.81 M |
-$4.00 M |
| Income Before Tax Ratio
|
-2.92
|
-2.49
|
0.3
|
-0.69
|
-2.77
|
0.48
|
-7.04
|
-13.82
|
-3.01
|
-0.65
|
| Income Tax Expense |
-$152,000.00 |
-$84,000.00 |
$13.41 M |
$5.24 M |
-$2.76 M |
$4.18 M |
$686,000.00 |
-$435,000.00 |
-$60,000.00 |
$291,000.00 |
| Net Income |
-$263.49 M |
-$280.32 M |
$127.84 M |
-$111.25 M |
-$94.73 M |
$99.94 M |
-$73.17 M |
-$62.97 M |
-$22.81 M |
-$4.00 M |
| Net Income Ratio |
-2.92 |
-2.49 |
0.27 |
-0.72 |
-2.69 |
0.46 |
-7.04 |
-13.72 |
-3.01 |
-0.65 |
| EPS |
-6.02 |
-6.5 |
3.01 |
-2.98 |
-2.58 |
2.73 |
-2.45 |
-2.38 |
-2.49 |
-0.3 |
| EPS Diluted |
-6.02 |
-6.5 |
2.91 |
-2.98 |
-2.58 |
2.73 |
-2.45 |
-2.38 |
-2.49 |
-0.3 |
| Weighted Average Shares
Out |
$43.73 M
|
$43.15 M
|
$42.44 M
|
$37.28 M
|
$36.69 M
|
$36.61 M
|
$29.86 M
|
$26.41 M
|
$9.17 M
|
$13.15 M
|
| Weighted Average Shares
Out Diluted |
$43.73 M
|
$43.15 M
|
$43.91 M
|
$37.28 M
|
$36.69 M
|
$36.65 M
|
$29.88 M
|
$26.41 M
|
$9.17 M
|
$13.15 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
